AR060992A1 - Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilamino, procedimientos para la preparacion de productos farmaceuticos, composiciones farmaceuticas que los comprenden y su uso en la elaboracion de un medicamento para la reduccion de la glucemia - Google Patents
Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilamino, procedimientos para la preparacion de productos farmaceuticos, composiciones farmaceuticas que los comprenden y su uso en la elaboracion de un medicamento para la reduccion de la glucemiaInfo
- Publication number
- AR060992A1 AR060992A1 ARP070102010A ARP070102010A AR060992A1 AR 060992 A1 AR060992 A1 AR 060992A1 AR P070102010 A ARP070102010 A AR P070102010A AR P070102010 A ARP070102010 A AR P070102010A AR 060992 A1 AR060992 A1 AR 060992A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- difenylpirimidinylamine
- glucemia
- procedures
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000004450 alkenylene group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 125000004419 alkynylene group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 4,5-diphenylpyrimidinylamino Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 150000001735 carboxylic acids Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006021874A DE102006021874B4 (de) | 2006-05-11 | 2006-05-11 | 4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060992A1 true AR060992A1 (es) | 2008-07-30 |
Family
ID=38326940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102010A AR060992A1 (es) | 2006-05-11 | 2007-05-09 | Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilamino, procedimientos para la preparacion de productos farmaceuticos, composiciones farmaceuticas que los comprenden y su uso en la elaboracion de un medicamento para la reduccion de la glucemia |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7713988B2 (enExample) |
| EP (1) | EP2024340B1 (enExample) |
| JP (1) | JP5277159B2 (enExample) |
| KR (1) | KR20090006845A (enExample) |
| CN (1) | CN101421251B (enExample) |
| AR (1) | AR060992A1 (enExample) |
| AU (1) | AU2007250211B2 (enExample) |
| BR (1) | BRPI0711393A2 (enExample) |
| CA (1) | CA2651657A1 (enExample) |
| DE (1) | DE102006021874B4 (enExample) |
| IL (1) | IL195177A0 (enExample) |
| MX (1) | MX2008014101A (enExample) |
| MY (1) | MY148096A (enExample) |
| NO (1) | NO20085066L (enExample) |
| TW (1) | TW200815366A (enExample) |
| UY (1) | UY30339A1 (enExample) |
| WO (1) | WO2007131620A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| US7582803B2 (en) | 2005-09-14 | 2009-09-01 | Amgen Inc. | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders |
| CA2662305C (en) | 2006-09-07 | 2012-04-17 | Amgen Inc. | Heterocyclic gpr40 modulators |
| EP2061760A1 (en) | 2006-09-07 | 2009-05-27 | Amgen, Inc | Benzo-fused compounds for use in treating metabolic disorders |
| ES2446419T3 (es) | 2007-04-16 | 2014-03-07 | Amgen, Inc | Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP5591706B2 (ja) | 2007-10-10 | 2014-09-17 | アムジエン・インコーポレーテツド | 置換ビフェニルｇｐｒ４０調節因子 |
| WO2009111056A1 (en) | 2008-03-06 | 2009-09-11 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
| AU2009303475B2 (en) | 2008-10-15 | 2012-09-13 | Amgen Inc. | Spirocyclic GPR40 modulators |
| MX2011006006A (es) * | 2008-12-08 | 2011-09-08 | Euroscreen Sa | Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos. |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8450350B2 (en) | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
| CA2798330A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| CN103298469A (zh) | 2010-08-31 | 2013-09-11 | 首尔大学校产学协力财团 | PPARδ激动剂的胎儿重编程的用途 |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN105142621A (zh) | 2012-10-24 | 2015-12-09 | 国家健康科学研究所 | 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂 |
| WO2015084692A1 (en) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10059667B2 (en) | 2014-02-06 | 2018-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| EP3273981B1 (en) | 2015-03-24 | 2020-04-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of diabetes |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003275242B2 (en) * | 2002-09-27 | 2010-03-04 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| NZ550114A (en) * | 2004-04-20 | 2011-02-25 | Transtech Pharma Inc | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
| DE102004039789A1 (de) * | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
-
2006
- 2006-05-11 DE DE102006021874A patent/DE102006021874B4/de not_active Expired - Fee Related
-
2007
- 2007-04-30 BR BRPI0711393-5A patent/BRPI0711393A2/pt not_active IP Right Cessation
- 2007-04-30 WO PCT/EP2007/003804 patent/WO2007131620A1/de not_active Ceased
- 2007-04-30 KR KR1020087027548A patent/KR20090006845A/ko not_active Abandoned
- 2007-04-30 JP JP2009508191A patent/JP5277159B2/ja not_active Expired - Fee Related
- 2007-04-30 EP EP07724731A patent/EP2024340B1/de not_active Not-in-force
- 2007-04-30 AU AU2007250211A patent/AU2007250211B2/en not_active Ceased
- 2007-04-30 CA CA002651657A patent/CA2651657A1/en not_active Abandoned
- 2007-04-30 CN CN2007800133035A patent/CN101421251B/zh not_active Expired - Fee Related
- 2007-04-30 MX MX2008014101A patent/MX2008014101A/es not_active Application Discontinuation
- 2007-05-09 AR ARP070102010A patent/AR060992A1/es not_active Application Discontinuation
- 2007-05-09 TW TW096116359A patent/TW200815366A/zh unknown
- 2007-05-10 UY UY30339A patent/UY30339A1/es not_active Application Discontinuation
-
2008
- 2008-11-06 MY MYPI20084448A patent/MY148096A/en unknown
- 2008-11-09 IL IL195177A patent/IL195177A0/en unknown
- 2008-11-10 US US12/267,918 patent/US7713988B2/en not_active Expired - Fee Related
- 2008-12-04 NO NO20085066A patent/NO20085066L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101421251B (zh) | 2011-10-19 |
| BRPI0711393A2 (pt) | 2011-11-01 |
| US20090149487A1 (en) | 2009-06-11 |
| EP2024340A1 (de) | 2009-02-18 |
| IL195177A0 (en) | 2009-08-03 |
| DE102006021874B4 (de) | 2008-03-27 |
| AU2007250211A1 (en) | 2007-11-22 |
| CA2651657A1 (en) | 2007-11-22 |
| MY148096A (en) | 2013-02-28 |
| NO20085066L (no) | 2009-02-06 |
| WO2007131620A1 (de) | 2007-11-22 |
| JP2009536627A (ja) | 2009-10-15 |
| CN101421251A (zh) | 2009-04-29 |
| MX2008014101A (es) | 2008-11-14 |
| EP2024340B1 (de) | 2012-07-18 |
| AU2007250211B2 (en) | 2011-11-10 |
| HK1130800A1 (en) | 2010-01-08 |
| UY30339A1 (es) | 2008-01-02 |
| KR20090006845A (ko) | 2009-01-15 |
| JP5277159B2 (ja) | 2013-08-28 |
| DE102006021874A1 (de) | 2007-11-22 |
| TW200815366A (en) | 2008-04-01 |
| US7713988B2 (en) | 2010-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060993A1 (es) | Acidos carboxilicos sustituidos con 4,5-difenilpirimidiniloxi o mercapto, procedimiento para su preparacion y su uso como productos farmaceuticos | |
| AR060991A1 (es) | Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilo y composiciones farmaceuticas que los contienen utilizadas para el tratamiento de la diabetes | |
| AR060990A1 (es) | Acidos carboxilicos sustituidos con fenilaminobenzoxazol y composiciones farmaceuticas que los contienen, utilizadas para el tratamiento de la diabetes | |
| AR035498A1 (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos, su uso en la preparacion de medicamentos, intermediarios para su preparacion y composiciones farmaceuticas que los contienen | |
| AR111572A2 (es) | Formas farmacéuticas que contienen vardenafilo | |
| AR073123A1 (es) | Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica | |
| AR003440A1 (es) | Nuevos derivados de aminoacidos, formulacion farmaceutica que los contiene, uso de dichos derivados para preparar medicamentos y procedimiento para la preparacion de dichos derivados. | |
| EA200701913A1 (ru) | Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом | |
| AR061238A1 (es) | Compuestos de oxilmilo macrociclico inhibidores de proteasa de hepatitis c | |
| CO6290631A2 (es) | Composición oral que contiene amino ácidos y un agente blanqueador | |
| ECSP055853A (es) | Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos | |
| CY1108700T1 (el) | Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης | |
| AR076778A1 (es) | Composiciones orales que contienen compuestos de poliguanidinio y metodos de preparacion y uso de las mismas | |
| AR029463A1 (es) | Pirrolidinas disustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento | |
| AR047928A1 (es) | Derivados de tetrahidropiridoindol | |
| AR065135A1 (es) | Compuestos triciclicos, composicion que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides. | |
| UY30339A1 (es) | Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilamino, procedimientos para su preparacion y su uso como productos farmacéuticos | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| AR082444A1 (es) | Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa | |
| AR013079A1 (es) | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios | |
| AR051340A1 (es) | Compuesto de c(4)- metoximetil acil pirrolidina, su uso para preparar un medicamento, formulacion farmaceutica que lo comprende y proceso para prepararlo | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| ECSP066330A (es) | Derivados de 1-sulfonilindol, su preparación y su uso como lingados de 5-ht-6 | |
| AR037560A1 (es) | Formulacion de altas dosis de ibandronato | |
| ECSP066325A (es) | Derivados de 5-indolilsulfonamidas, su preparación y su uso como moduladores de 5-ht-6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |